MedPath

on-Interventional Study to Assess the Clinical Outcome in Patients Treated for Poorly Differentiated (High-Grade, G3) Neuroendocrine Carcinomas Except Primary Lung Cancer

Recruiting
Conditions
Poorly differentiated (G3) neuroendocrine carcinomas except primary lung cancer
C75.9
Endocrine gland, unspecified
Registration Number
DRKS00005433
Lead Sponsor
OSHO,Ostdeutsche Studiengruppe für Hämatologie und Onkologie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

Patients with poorly differentiated (G3) neuroendocrine carcinoma except primary lung cancer

Exclusion Criteria

primary lung cancer G3

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Overall survival after first diagnosis
Secondary Outcome Measures
NameTimeMethod
Response to primary and salvage treatment regimens; progression-free survival, treatment-related adverse events
© Copyright 2025. All Rights Reserved by MedPath